Rapid reduction in plaque inflammation by sonodynamic therapy inpatients with symptomatic femoropopliteal peripheral artery disease:A randomized controlled trial

Jiang, Yongxing; Fan, Jingxue; Li, Yong; Wu, Guodong; Wang, Yuanqi; Yang, Jiemei; Wang, Mengjiao; Cao, Zhengyu; Li, Qiannan; Wang, Hui; Zhang, Zhengyan; Wang, Yu; Li, Bicheng; Sun, Fengyu; Zhang, Haiyu; Zhang, Zhiguo; Li, Kang; Tian, Ye

doi:10.1016/j.ijcard.2020.09.035

Cited by 21 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown the SDT-induced foam-cell apoptosis, iron retention alleviation and cytokine secretion inhibition contributed to the stabilization in advanced plaques by using 5aminolevulinic acid, sinoporphyrin sodium, etc [59,61]. Advanced progress has been achieved in clinical trials [65]. The latest work on developing theragnostic materials (PFP-HMME@PLGA/MnFe 2 O 4 -ramucirumab) for atherosclerotic plaque neovascularization was reported by Yao et al [64].…”

Section: Othersmentioning

confidence: 99%

Emerging diagnostic and therapeutic technologies based on ultrasound-triggered biomaterials

et al. 2023

View full text Add to dashboard Cite

Ultrasound (US) is a kind of acoustic waves with frequency higher than 20 kHz. Learning from the echo detection ability of bats and dolphins, scientists applied US for clinical imaging by sending out US waves and detecting echo with shifted intensities and frequencies from human tissue. US has long been played a critical role in noninvasive, real-time, low cost and portable diagnostic imaging. With the in-depth study of US in multidisciplinary fields, US and US-responsive materials has shown practical value in not only disease diagnosis, but also disease treatment. In this review, we introduce the lately proposed and representative US-responsive materials for biomedical applications, including diagnostic and therapeutic applications. We focused on US-mediated physiochemical therapies, such as sonodynamic therapy, high-intensity focused US ablation, sonothermal therapy, thrombolysis, etc., and US-controlled delivery of chemotherapeutics, gas, gene, protein, and bacteria. We also conclude the current challenges facing the clinical translation of the smart US-responsive materials and prospect future development of US medicine.

show abstract

Section: Othersmentioning

confidence: 99%

Emerging diagnostic and therapeutic technologies based on ultrasound-triggered biomaterials

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A few examples of these registries and trials are listed in Table 2. [42][43][44][45][46][47][48][49][50][51][52][53][54][55] For example, the EUCLID trial included the EQ-5D, VAS, and PAQ, 43 while the CLEVER trial used the SF-12, PAQ, and WIQ. 4 Most commonly, the PAQ and VascuQOL are used (disease-specific), along with the SF-36, SF-12, or EQ-5D (generic) (Table 2).…”

Section: Expansion Of Validation Evidence Basementioning

confidence: 99%

Patient-Reported Outcome Measures in Symptomatic, Non–Limb-Threatening Peripheral Artery Disease: A State-of-the-Art Review

Rymer

Narcisse

Cosiano

et al. 2022

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Patient-reported outcome measures (PROMs) are health outcomes directly reported by the patient that can be used to measure the effect of disease and treatments on patient perceived well-being. This review summarizes current evidence regarding the validation of PROMs in people with symptomatic, nonlimb-threatening peripheral artery disease. A literature search was conducted to identify studies of symptomatic peripheral artery disease without limb-threatening ischemia that included PROMs and had sample sizes ≥25. PROMs were summarized along a continuum of validation using classical test theory framework and according to whether they fulfilled defined criteria for (1) content validity; (2) psychometric validation; and (3) further validation evidence base expansion. Of 2198 articles identified, 157 (7.1%) met inclusion criteria. Twenty-four PROMs in patients with symptomatic peripheral artery disease were reviewed. Among disease-specific PROMs, 8 of 15 had excellent reliability as measured by a Cronbach alpha ≥0.80. Based on established criteria for PROM responsiveness, 6 of 15 disease-specific PROMs demonstrated excellent sensitivity to change. Of these, the disease-specific peripheral artery questionnaire, vascular quality of life questionnaire, and walking impairment questionnaire met criteria for validation at each stage of the continuum. For generic (nondisease specific) PROMs, the European Quality of Life 5-Dimension and SF-36 had the most extensive evidence of validation. Evidence from this review can inform selection of PROMs aligned with scientific and clinical goals, given the variable degree of validation and potential complementary nature of the measures.

show abstract

“…However, only a limited number of recent studies have specifically evaluated the utility of 18 F-FDG PET as a tool for quantifying arterial inflammation in patients with PAD. One recent study by Jiang et al (37) applied serial 18 F-FDG PET/CT imaging in PAD patients before and after sonodynamic therapy to the femoropopliteal artery, which demonstrated that PET/CT imaging could detect and quantify therapeutic reductions in arterial inflammation in the setting of PAD. Another recent study focused on evaluating the utility of a combined 18 F-FDG PET and MR imaging approach for simultaneous assessment of both plaque morphology and arterial inflammation in a small sample size of PAD patients, but did not find any significant correlations between 18 F-FDG arterial uptake and histological measures of arterial inflammation (38).…”

Section: Molecular Imaging Of Peripheral Artery Inflammation and Atherosclerosismentioning

confidence: 99%

Molecular Imaging of Lower Extremity Peripheral Arterial Disease: An Emerging Field in Nuclear Medicine

Stacy

2022

Front. Med.

View full text Add to dashboard Cite

Peripheral arterial disease (PAD) is an atherosclerotic disorder of non-coronary arteries that is associated with vascular stenosis and/or occlusion. PAD affecting the lower extremities is characterized by a variety of health-related consequences, including lifestyle-limiting intermittent claudication, ulceration of the limbs and/or feet, increased risk for lower extremity amputation, and increased mortality. The diagnosis of lower extremity PAD is typically established by using non-invasive tests such as the ankle-brachial index, toe-brachial index, duplex ultrasound, and/or angiography imaging studies. While these common diagnostic tools provide hemodynamic and anatomical vascular assessments, the potential for non-invasive physiological assessment of the lower extremities has more recently emerged through the use of magnetic resonance- and nuclear medicine-based approaches, which can provide insight into the functional consequences of PAD-related limb ischemia. This perspectives article specifically highlights and discusses the emerging applications of clinical nuclear medicine techniques for molecular imaging investigations in the setting of lower extremity PAD.

show abstract

Rapid reduction in plaque inflammation by sonodynamic therapy inpatients with symptomatic femoropopliteal peripheral artery disease:A randomized controlled trial

Cited by 21 publications

References 30 publications

Emerging diagnostic and therapeutic technologies based on ultrasound-triggered biomaterials

Emerging diagnostic and therapeutic technologies based on ultrasound-triggered biomaterials

Patient-Reported Outcome Measures in Symptomatic, Non–Limb-Threatening Peripheral Artery Disease: A State-of-the-Art Review

Molecular Imaging of Lower Extremity Peripheral Arterial Disease: An Emerging Field in Nuclear Medicine

Contact Info

Product

Resources

About